Bendamustine can severely impair T-cell immunity against cytomegalovirus

Toru HosodaDepartment of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Akihiro YokoyamaDepartment of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, JapanCorrespondence[email protected]

Mie YonedaDepartment of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Ryusuke YamamotoDepartment of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Kota OhashiDepartment of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Toshiya KagooDepartment of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Hironori UenoDepartment of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Saigen BokuDepartment of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Takahiro YanoDepartment of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

show all

References

Gratama JW, van Esser JW, Lamers CH, et al. Tetramer-based quantification of cytomegalovirus-specific CD8 + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001;98: 1358–1364.
PubMed Web of Science ®Google Scholar
Robinsin KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473–4479.
PubMed Web of Science ®Google Scholar
Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin's lymphoma: results from a multicenter study. Cancer 2010;116:106–114.
PubMed Web of Science ®Google Scholar
Lim SH, Pathapati S, Langevin J, et al. Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine. Ann Hematol 2012;91:643–644.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Bendamustine can severely impair T-cell immunity against cytomegalovirus

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Bendamustine can severely impair T-cell immunity against cytomegalovirus

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date